Skip to Content

Ocaliva Approval History

Ocaliva (obeticholic acid) is a first-in-class farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis.

Development History and FDA Approval Process for Ocaliva

DateArticle
May 27, 2016Approval FDA Grants Accelerated Approval to Ocaliva (obeticholic acid) for Primary Biliary Cholangitis
Apr 10, 2016FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva (obeticholic acid) for the Treatment of Primary Biliary Cirrhosis
Dec 17, 2015FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBC
Aug 31, 2015FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
Jun 29, 2015Intercept Pharmaceuticals Submits NDA for Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
May 19, 2015Intercept Pharmaceuticals Announces Pivotal Phase 3 Clinical Trial of Obeticholic Acid in NASH
Mar 31, 2011Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide